A Multicenter Randomized, Controlled Phase III Clinical Trial of Pembrolizumab Plus Paclitaxel and Cisplatin Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma (KEYSTONE-002)
Latest Information Update: 20 Dec 2023
At a glance
- Drugs Cisplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms KEYSTONE-002
- 26 May 2022 Planned primary completion date changed from 1 May 2023 to 31 Dec 2023.
- 23 Mar 2021 New trial record